A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
A Multi-site, Open-label, Sequential-group, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Email contact via H. Lundbeck A/S
- Phone Number: +45 36301311
- Email: HQ_Medinfo@Lundbeck.com
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Recruiting
- Rigshospitalet
-
-
-
-
-
Angers, France, 49933
- Recruiting
- CHU Angers
-
Lille, France, 59000
- Recruiting
- CHU de Lille
-
Paris, France, 75013
- Recruiting
- GH Pitié-Salpêtrière
-
Strasbourg, France, 67091
- Recruiting
- CHRU Strasbourg
-
-
-
-
-
Tbilisi, Georgia, 0144
- Recruiting
- David Metreveli Medical Centre, Tbilisi
-
-
-
-
-
Dublin, Ireland, D02 YN77
- Recruiting
- Beaumont Hospital Royal College of Surgeons in Ireland (RCSI), Dublin
-
-
-
-
-
Bologna, Italy, 40138
- Recruiting
- Azienda Ospedaliero Universitaria di Bologna
-
Roma, Italy, 00161
- Recruiting
- Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma
-
-
-
-
-
Dobry Lekarz, Poland, 60-324
- Recruiting
- Centrum Nowoczesnych Terapii, Dobry Lekarz
-
-
-
-
-
Gothenburg, Sweden, 413 45
- Recruiting
- Sahlgrenska University Hospital
-
Stockholm, Sweden, 17174
- Recruiting
- Karolinska University Hospital
-
-
-
-
-
Birmingham, United Kingdom, B15 2TH
- Recruiting
- NIHR/Wellcome Trust Clinical Research Facility
-
Cambridge, United Kingdom, CB2 0SL
- Recruiting
- Cambridge Clinical Research Centre
-
London, United Kingdom, SE1 9RT
- Recruiting
- NIHR Clinical Research Facility
-
London, United Kingdom, W1T 7HA
- Recruiting
- University College London Hospital - NIHR
-
-
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University Hospital-University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Parts A and B:
- Confirmed diagnosis of 21-hydroxylase deficiency CAH (based on a pathogenic CYP21A2 variant and/or elevated 17-OHP).
- Morning (pre-glucocorticoid [GC] replacement dose) blood concentrations of 17-OHP >4-times upper limit of normal (ULN).
- Body mass index (BMI) ≥18.5 kilograms (kg)/square meter (m^2) (minimum 50 kg) and ≤40 kg/m^2.
- Stable GC replacement therapy for ≥1 month prior to the Screening Visit.
- For the salt-wasting form of CAH, the participant must have been on a stable dose of mineralocorticoid replacement for ≥3 months prior to the Screening Visit.
- Apart from CAH, the participant is generally healthy in the opinion of the investigator and based on medical history, physical examination, vital signs, ECGs, and the results of the safety laboratory tests.
Part C:
- Confirmed diagnosis of 21-hydroxylase deficiency CAH (based on a pathogenic CYP21A2 variant and/or elevated 17-OHP).
- For Cohort C1 only: Morning (pre-GC replacement dose) blood concentrations of androgens (A4) > ULN for age and sex.
- For Cohort C2 only: Morning (pre-GC replacement dose) blood concentrations of androgens (A4) ≤ ULN for age and sex and the participant is treated with high doses of GC.
- Stable GC replacement therapy for ≥1 month prior to the Screening Visit.
- For the salt-wasting form of CAH, the participant must have been on a stable dose of mineralocorticoid replacement for ≥1 month prior to the Screening Visit.
Exclusion Criteria:
- The participant is pregnant or breastfeeding.
- The participant has a clinically significant abnormal laboratory value, electrocardiogram (ECG) parameter, or vital signs value, or other safety findings at the Screening Visit that indicate a potential risk for the participant if enrolled, in the opinion of the investigator.
- The participant has a history of known hypersensitivity or intolerance to Lu AG13909 or its excipients.
Part C Only:
- The participant has received at least one dose of Lu AG13909 in Part A or Part B.
Other inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lu AG13909
Participants in Part A will receive multiple intravenous (IV) doses of Lu AG13909 per a prespecified dosing schedule.
After data from Part A has shown that a pharmacologically relevant dose level is safe and tolerable, participants in Part B will then receive multiple IV doses of Lu AG13909 per a prespecified dosing schedule.
After data from Part B has shown that a pharmacologically relevant dose level is safe and tolerable, participants in Part C will then receive multiple IV doses of Lu AG13909 per a prespecified dosing schedule.
Participants from Part C may be eligible to continue in the optional Treatment Extension.
|
Solution for infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Up to Day 161
|
Up to Day 161
|
|
Parts A and B: Number of Participants With Anti-Drug Antibodies (ADAs)
Time Frame: Day 1 up to Day 161
|
Day 1 up to Day 161
|
|
Parts A and B: Cmax: Maximum Observed Serum Concentration of Lu AG13909
Time Frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
|
Parts A and B: Tmax: Nominal Time Corresponding to the Occurrence of Cmax
Time Frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
|
Parts A and B: Ctrough: Minimum Observed Serum Concentration of Lu AG13909
Time Frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
|
Parts A and B: t½: Apparent Elimination Half-life of Lu AG13909
Time Frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
|
Parts A and B: AUC0-infinity: Area under the plasma concentration curve of x from zero to infinity of Lu AG13909
Time Frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
|
Parts A and B: CL: Apparent Total Serum Clearance of Lu AG13909
Time Frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
|
Parts A and B: Vz: Volume of Distribution During the Terminal Elimination Phase After IV Administration of Lu AG13909
Time Frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
|
Parts A and B: Change From Baseline After Each Dose of Lu AG13909 in Blood Concentrations of 17-hydroxyprogesterone (17-OHP) and Androstenedione (A4)
Time Frame: Baseline up to Day 85
|
Baseline up to Day 85
|
|
Parts A and B: AUC0-tau: Area under the curve over a dosing interval
Time Frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
0 (predose) up to 24 hours postdose on Day 1 to Day 161
|
|
Part C: Morning Concentration of A4 in Blood <Upper Limit of Normal (ULN)
Time Frame: Day 169
|
Day 169
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part C: Lu AG13909 Serum Concentrations Following Multiple IV Doses
Time Frame: Baseline up to Day 352
|
Baseline up to Day 352
|
|
Part C: Change From Baseline of Lu AG13909 in Blood Concentrations of 17-OHP and A4
Time Frame: Baseline up to Day 169
|
Baseline up to Day 169
|
|
Part C: Number of Participants With TEAEs
Time Frame: Baseline up to Day 352
|
Baseline up to Day 352
|
|
Part C: Number of Participants With ADAs
Time Frame: Baseline up to Day 352
|
Baseline up to Day 352
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Email contact via H. Lundbeck A/S, HQ_Medinfo@Lundbeck.com
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Endocrine System Diseases
- Male Urogenital Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Gonadal Disorders
- Congenital Abnormalities
- Adrenal Gland Diseases
- Disorders of Sex Development
- Urogenital Abnormalities
- Steroid Metabolism, Inborn Errors
- Adrenogenital Syndrome
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Adrenal Hyperplasia, Congenital
Other Study ID Numbers
Other Study ID Numbers
- 19873A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.